Loading
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Latest quote
$1.40
$0.00 · 0.00%
After-hours
$1.40
$0.00 · 0.00%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Day range
Current $1.40
52-week range
Current $1.40
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
47
Mixed
Risk
59
Elevated Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Day range
Current $1.40
52-week range
Current $1.40
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 6.69M USD | 2.56K USD | 7.51M USD | 6.75M USD | 13K USD |
| Gross profit | −6.69M USD | −2.56K USD | −7.51M USD | −6.75M USD | −13K USD |
| Research and development | 1.81M USD | 2.25M USD | 8.24M USD | 6.34M USD | 1.61M USD |
| Selling, general, and administrative | — | 4.93M USD | — | 6.75M USD | 4.93M USD |
| Operating expenses | 1.81M USD | 7.19M USD | 8.24M USD | 6.34M USD | 6.22M USD |
| Interest income | 32.1K USD | 5.47K USD | — | — | — |
| Interest expense | 473.94K USD | 883.65K USD | 1.05M USD | 96.69K USD | — |
| Depreciation and amortization | 1.82K USD | 2.56K USD | 3.87K USD | 3.8K USD | 2.33K USD |
| Operating income | −8.5M USD | −7.19M USD | −15.75M USD | −13.09M USD | −6.23M USD |
| Net income | −8.95M USD | −4.71M USD | −16.83M USD | −13.27M USD | −5.43M USD |
Company facts updated Sep 15, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
257.14% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
